Paul Weiss Expands Life Sciences Practice with Partner Ian Edvalson in San Francisco

Paul, Weiss, Rifkind, Wharton & Garrison LLP has announced the addition of Ian Edvalson as a partner in its Corporate Department based in San Francisco. This strategic hire is designed to bolster the firm’s life sciences transactions and intellectual property capabilities, particularly in the biopharmaceutical and medical technology sectors.

Edvalson’s practice focuses on transactions involving both public and private life sciences companies. His expertise encompasses licensing and collaboration agreements, intellectual property considerations in mergers and acquisitions, and other commercial arrangements that support the development and commercialization of life sciences products and services.

The firm highlighted that Edvalson’s arrival will enhance Paul, Weiss’s ability to advise clients on complex strategic transactions where intellectual property, technology, and commercialization rights are central to deal structures.

His work spans the entire lifecycle of life sciences transactions, including agreements governing the development, licensing, and commercialization of pharmaceutical and biotechnology assets.

Paul, Weiss emphasized that Edvalson’s experience will complement its Intellectual Property & Technology Transactions Practice. This practice collaborates closely with the firm’s corporate teams on transactions involving patents, technology, and other intangible assets.

The practice advises clients on integrating intellectual property assets within broader deal frameworks and develops transactional strategies aimed at identifying opportunities and mitigating IP-related risks.

Ian Edvalson has been recognized by Chambers USA in the Life Sciences: Corporate/Commercial – California category since 2021, with prior recognition spanning from 2007 through 2014.

His academic credentials include a bachelor’s degree in Korean and a Bachelor of Science in Molecular Biology from Brigham Young University, followed by a law degree from the University of Chicago Law School.

Paul, Weiss currently employs over 1,500 lawyers worldwide, advising corporations, financial institutions, and asset managers across corporate transactions, litigation, and restructuring matters.

Jeffrey Osterman, Global Co-Head of Intellectual Property & Technology Transactions and Chair of Life Sciences Licensing & Collaboration Transactions at Paul, Weiss, commented on the hire: “Ian’s work across the entire spectrum of life sciences transactions will be incredibly valuable to our clients as we continue to support them on their most complex deals and commercial agreements in the sector. We are thrilled to welcome him to the firm.”

Osterman further added, “Ian brings a stellar track record of providing the sophisticated counsel that life sciences companies need to execute pivotal transactions, including licensing and collaboration agreements. He is a terrific lawyer whose commercial and strategic approach will strengthen our growing IP practice.”

This move reflects Paul, Weiss’s ongoing commitment to expanding its life sciences and intellectual property transactional capabilities to meet the evolving needs of clients in these dynamic sectors.